737 related articles for article (PubMed ID: 9751634)
1. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
2. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression.
Rosen J; He M; Umbricht C; Alexander HR; Dackiw AP; Zeiger MA; Libutti SK
Surgery; 2005 Dec; 138(6):1050-6; discussion 1056-7. PubMed ID: 16360390
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 is a presurgical marker of human thyroid carcinoma.
Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A
Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965
[TBL] [Abstract][Full Text] [Related]
4. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
5. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
6. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
Puskas LG; Juhasz F; Zarva A; Hackler L; Farid NR
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(2):177-86. PubMed ID: 16171553
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity in "suspicious" thyroid cytology.
Lerma E; Mora J
Cancer; 2005 Dec; 105(6):492-7. PubMed ID: 16104043
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma.
Guerra LN; Miler EA; Moiguer S; Karner M; Orlandi AM; Fideleff H; Burdman JA
Clin Chim Acta; 2006 Aug; 370(1-2):180-4. PubMed ID: 16600201
[TBL] [Abstract][Full Text] [Related]
9. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
12. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations.
Tallini G; Dal Cin P; Rhoden KJ; Chiapetta G; Manfioletti G; Giancotti V; Fusco A; Van den Berghe H; Sciot R
Am J Pathol; 1997 Jul; 151(1):37-43. PubMed ID: 9212729
[TBL] [Abstract][Full Text] [Related]
13. Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker.
Abe N; Watanabe T; Sugiyama M; Uchimura H; Chiappetta G; Fusco A; Atomi Y
Cancer Res; 1999 Mar; 59(6):1169-74. PubMed ID: 10096541
[TBL] [Abstract][Full Text] [Related]
14. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction.
Bernet VJ; Anderson J; Vaishnav Y; Solomon B; Adair CF; Saji M; Burman KD; Burch HB; Ringel MD
J Clin Endocrinol Metab; 2002 Oct; 87(10):4792-6. PubMed ID: 12364475
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
Belge G; Meyer A; Klemke M; Burchardt K; Stern C; Wosniok W; Loeschke S; Bullerdiek J
Genes Chromosomes Cancer; 2008 Jan; 47(1):56-63. PubMed ID: 17943974
[TBL] [Abstract][Full Text] [Related]
17. HMGI(Y) gene expression as a potential marker of thyroid follicular carcinoma.
Czyz W; Balcerczak E; Jakubiak M; Pasieka Z; Kuzdak K; Mirowski M
Langenbecks Arch Surg; 2004 Jun; 389(3):193-7. PubMed ID: 15107999
[TBL] [Abstract][Full Text] [Related]
18. HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR.
Jin L; Lloyd RV; Nassar A; Lappinga PJ; Sebo TJ; Swartz K; Seys AR; Erickson-Johnson MR; Roth CW; Evers BR; Oliveira AM; Zhang J
Diagn Mol Pathol; 2011 Jun; 20(2):71-80. PubMed ID: 21532495
[TBL] [Abstract][Full Text] [Related]
19. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
20. Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?
Letsas KP; Vartholomatos G; Tsepi C; Tsatsoulis A; Frangou-Lazaridis M
Neoplasma; 2007; 54(1):57-62. PubMed ID: 17203893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
